Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The α2β1 integrin is a metastasis suppressor in mouse models and human cancer
Norma E. Ramirez, … , Andries Zijlstra, Mary M. Zutter
Norma E. Ramirez, … , Andries Zijlstra, Mary M. Zutter
Published December 6, 2010
Citation Information: J Clin Invest. 2011;121(1):226-237. https://doi.org/10.1172/JCI42328.
View: Text | PDF
Research Article Oncology Article has an altmetric score of 4

The α2β1 integrin is a metastasis suppressor in mouse models and human cancer

  • Text
  • PDF
Abstract

Integrins regulate cell-cell and cell-matrix adhesion and thereby play critical roles in tumor progression and metastasis. Although work in preclinical models suggests that β1 integrins may stimulate metastasis of a number of cancers, expression of the β1 subunit alone has not been shown to be a useful prognostic indicator in human cancer patients. Here we have demonstrated that the α2β1 integrin suppresses metastasis in a clinically relevant spontaneous mouse model of breast cancer. These data are consistent with previous studies indicating high expression of α2β1 integrin in normal breast epithelium and loss of α2β1 in poorly differentiated breast cancer. They are also consistent with our systematic analysis of microarray databases of human breast and prostate cancer, which revealed that decreased expression of the gene encoding α2 integrin, but not genes encoding α1, α3, or β1 integrin, was predictive of metastatic dissemination and decreased survival. The predictive value of α2 expression persisted within both good-risk and poor-risk cohorts defined by estrogen receptor and lymph node status. Thus, the α2β1 integrin functionally inhibits breast tumor metastasis, and α2 expression may serve as an important biomarker of metastatic potential and patient survival.

Authors

Norma E. Ramirez, Zhonghua Zhang, Aasakiran Madamanchi, Kelli L. Boyd, Lynda D. O’Rear, Abudi Nashabi, Zhengzi Li, William D. Dupont, Andries Zijlstra, Mary M. Zutter

×

Figure 7

Expression of the α2β1 integrin predicts metastasis and survival in high- and low-risk cohorts.

Options: View larger image (or click on image) Download as PowerPoint
Expression of the α2β1 integrin predicts metastasis and survival in high...
(A–D). The clinical importance of α2β1 integrin expression levels in good-risk or poor-risk subpopulations was determined using a log-rank analysis of the NKI-295 cohort. Expression of high levels of α2 integrin correlated with decreased metastasis and increased survival in both high-risk and low-risk subgroups (A, lymph node positive, P = 0.0049; B, lymph node negative, P = 0.0084; C, ER+, P = 0.001; D, ER–, P = 0.1482). (E) For patients in this cohort with known metastatic disease at presentation, decreased survival significantly correlated with decreased α2 integrin expression (E, P = 0.004). (F) To validate the correlation between α2 integrin expression and outcome among lymph node–negative patients a separate publicly available microarray analysis of 286 breast cancer patients (Wang cohort) was analyzed. In this separate cohort, α2 integrin expression correlated with increased disease-free survival in a second lymph node–negative cohort (F, P = 0.0317).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 1 patents
Highlighted by 1 platforms
140 readers on Mendeley
See more details